Sequential Couplets of Cisplatin/Topotecan and Cisplatin/Paclitaxel as First-Line Therapy in Advanced Epithelial Ovarian Cancer

University of Pennsylvania Cancer Center
Ultima Vez Modificado: 16 de mayo del 1999

Share article

Dr. P. Hoskins presented a Phase II trial of sequential couplets of cisplatin (DDP) and topotecan (TOP) and cisplatin and paclitaxel (T) as first-line therapy for advanced epithelial ovarian cancer on behalf of the National Cancer Institute of Canada. The dosage used were as follows:

DDP/TOP cycles: DDP 50 mg/m2 and TOP 0.75 mg/m2

DDP/T cycles: DDP 75 mg/m2 and T 135 mg/m2 IV infusion over 24 hours

Interval debulking was allowed.

Dr. Hoskins reported that:

  • Dose reduction was needed in 13% of DDP/TOP cycles

  • Dose delays were incurred in 9% of DDP/TOP cycles

  • A response rate of 85%
Dr. Hoskins concluded that:
  • Myelotoxcity of this couplet regimen is high but does not prevent delivery.

  • The response rate is encouraging being that these were predominately suboptimal patients.
This presentation was discussed by David Spriggs, M.D. from Memorial Sloan-Kettering Cancer Center. Dr. Spriggs had reservations:
  • Cisplatin was used instead of carboplatin

  • Marked reduction in topotecan dosing

  • Treatment delay was common

  • Substantial toxicity

I Wish You Knew

How cancer patients have changed my life

View More

Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.

OncoLink OncoPilot

Frente a un nuevo diagnóstico de cáncer o de cambiar el curso de su tratamiento actual? Deje que nuestro personal de enfermería cáncer que ayudan a pasar!

Más información